Author Correction: Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells

Correction to: Acta Pharmacol Sin 10.1038/aps.2016.85, published online 12 Sep 2016

It just came to the author’s attention that three errors were introduced into the paper during the stage of figure preparation. Specifically, the Western blotting bands of GAPDH in Fig. 2b as well as Fig. 3b, cv PARP in HCC827/GR6 cells (Fig. 3b) and IHC staining images of EGFR and Hsp70 in group gefitinib 50 mg/kg (Fig. 5d) were found to be misplaced inadvertently. These errors were made completely by accident. Under no circumstance did the authors falsify or “make up” data in order to mislead the reviewers or readers.

Fig. 2b.

Impact of FS-108 on G₂/M transition regulators. HCC827, HCC827/GR6, NCI-H1650, and NCI-H1975 cells were treated with gefitinib or FS-108 at the indicated concentrations for 24 h and the cell lysates were immunoblotted with the indicated antibodies.

Fig. 3b.

Modulation of FS-108 on apoptotic proteins. HCC827, HCC827/GR6, NCI-H1650, and NCI-H1975 cells were treated with gefitinib or FS-108 at the indicated concentrations for 72 h and analyzed by immunoblotting with the indicated antibodies.

Fig. 5d.

Effects of FS-108 on the modulation of protein expression in vivo. The immunohistochemical evaluation of the basal expression of EGFR, Akt, and Hsp70 is presented.

These corrections do not affect the scientific conclusions of each section and the entire paper. Nonetheless, the authors sincerely apologize for any inconvenience this might have caused.

The corrected figure panels of Fig. 2b, 3b and 5d are presented as follows: